United States · FDA National Drug Code directory
ANDEXXA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0310-3200_7c42c928-30f8-44ac-a040-d3087b2d6074
- Product NDC
- 0310-3200
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- andexanet alfa
- Labeler
- AstraZeneca Pharmaceuticals LP
- Marketing category
- BLA
- Marketing start / end (source format)
- 20220712 / 20271231
Source-listed ingredients
- ANDEXANET ALFA — 200 mg/20mL
These values do not establish equivalence or a dose recommendation.
Packages
- 4 VIAL, SINGLE-USE in 1 CARTON (0310-3200-04) / 20 mL in 1 VIAL, SINGLE-USE (0310-3200-01) · 0310-3200-04
- 5 VIAL, SINGLE-USE in 1 CARTON (0310-3200-05) / 20 mL in 1 VIAL, SINGLE-USE (0310-3200-01) · 0310-3200-05
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →